Covid 19 Research using Clinical Trials (Home Page)
Report for D015673: Fatigue Syndrome, Chronic NIH
(Synonyms: Fatigue Syndrome, Chroni, Fatigue Syndrome, Chronic)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
There is one clinical trial.
Clinical Trials
1 Chronic Fatigue Etiology and Recovery in Covid-19 Patients in Intensive Care Unit : the Role of Fatigability
Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This symptom seems particularly pronounced in Covid-19 patients and may affect their quality of life by decreasing their capacity to perform simple tasks of daily life. The aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in the feeling of fatigue of Covid-19 patients. Because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. A better knowledge of chronic fatigue etiology and its recovery will allow to optimize rehabilitation treatments to shorten the persistence of chronic fatigue and in fine improve life quality.
NCT04363606 Chronic Fatigue Syndrome Intensive Care Unit Muscle Other: Questionnaires Biological: blood test Other: Maximal effort test Device: actigraphy Device: Neuromuscular evaluation MeSH:Fatigue Syndrome, Chronic Fatigue
HPO:Fatigue
Primary Outcomes
Measure: voluntary maximum force reduction Time: 6 weeks post-discharge
Secondary Outcomes
Description: Level of cortical activation and cortico-spinal excitability measured by transcranial magnetic stimulation
Measure: Neuromuscular function : cortical activity Time: 6 weeks post-discharge
Description: Peripheral function by electrical nerve stimulation
Measure: Neuromuscular function : Peripheral function Time: 6 weeks post-discharge
Description: measured by effort test
Measure: Maximal oxygen uptake (VO2max) Time: 6 weeks post-discharge
Description: measured by actigraphy
Measure: quality of sleep Time: 6 weeks post-discharge
Description: with Magnetic resonance imaging
Measure: muscle volume Time: 6 weeks post-discharge
Description: measured by a Phosphorus 31 Nuclear magnetic resonance test
Measure: metabolic fatigue Time: 6 weeks post-discharge
HPO Nodes
Primary Outcomes
Measure: voluntary maximum force reduction Time: 6 weeks post-dischargeSecondary Outcomes
Description: Level of cortical activation and cortico-spinal excitability measured by transcranial magnetic stimulation
Measure: Neuromuscular function : cortical activity Time: 6 weeks post-dischargeDescription: Peripheral function by electrical nerve stimulation
Measure: Neuromuscular function : Peripheral function Time: 6 weeks post-dischargeDescription: measured by effort test
Measure: Maximal oxygen uptake (VO2max) Time: 6 weeks post-dischargeDescription: measured by actigraphy
Measure: quality of sleep Time: 6 weeks post-dischargeDescription: with Magnetic resonance imaging
Measure: muscle volume Time: 6 weeks post-dischargeDescription: measured by a Phosphorus 31 Nuclear magnetic resonance test
Measure: metabolic fatigue Time: 6 weeks post-discharge